Induction immunosuppression after lung transplantation

Lung transplantation is currently the best treatment available for patients suffering from severe lung diseases. However, despite significant advancements, some patients face severe complications, especially due to rejection by their immune system. One particularly challenging form of rejection is caused by antibodiessubstances naturally produced by the body to protect against infections. Unfortunately, when antibodies mistakenly target a transplanted lung, it can lead to severe organ damage, significantly reducing the patients survival chances. Currently, medical professionals do not fully understand how this antibody-driven rejection occurs, nor do they have reliable treatments to prevent or stop it. Our project aims to closely examine how common medications used immediately after lung transplantationknown as induction therapiesaffect a type of immune cell called B cells, which produce antibodies. Preliminary studies suggest that while these medications effectively control certain immune responses, they may inadvertently promote conditions where harmful antibodies can flourish. By studying different induction therapies, both directly in patients after transplantation and in laboratory settings, we hope to identify exactly how these therapies influence B cell behavior. This research is groundbreaking as it addresses a critical gap in our understanding of the immune system after lung transplantation. With clearer insights, doctors could potentially prevent dangerous antibody reactions, improving patient outcomes and longevity after transplantation.